AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05514925
Drug: Bevacizumab Injection [Avastin]
RxNorm normalized name: bevacizumab Injection [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of bevacizumab (1.25 mg, 0.05 ml) in the inferior temporal quadrant of the eye, 4 mm behind the limbus in phakic eyes, and 3.5 mm in pseudophakic eyes.
Trial: NCT00565240
Drug: Marvelon
RxNorm normalized name: isopropyl alcohol
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral contraceptive
Trial: NCT00565240
Drug: Nuvaring
RxNorm normalized name: NuvaRing
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: contraceptive vaginal ring
Trial: NCT00565240
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aromatase Inhibitors
Trial: NCT02052752
Drug: 3% Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Trial: NCT02052752
Drug: 3% Benzoyl Peroxide Placebo
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Trial: NCT02348593
Drug: JZP-110
RxNorm normalized name: JZP-386 free base
DrugBank: JZP-386 free base (DB17068)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00928304
Drug: Florbetaben (BAY94-9172)
RxNorm normalized name: florbetaben
DrugBank: Florbetaben F-18 (DB09148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
Trial: NCT00149890
Drug: Basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight \<35 kg) or 20 mg (body weight ≥35 kg) strength.
Trial: NCT00893061
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00893061
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00893061
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00893061
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01125761
Drug: dexamethasone 0.5 mg and 1.0 mg clemastine cream
DrugBank: Clemastine (DB00283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
Trial: NCT01125761
Drug: Dexamethasone 0,5 mg cream
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
Trial: NCT04705922
Drug: TT-00420 Capsule
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TT-00420 capsule formulation, administered orally
Trial: NCT04705922
Drug: TT-00420 Tablet
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TT-00420 tablet formulation, administered orally
Trial: NCT00212056
Drug: ANP(hANP)
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0∙025 μg/kg per min for 3 days(intravenous)
Trial: NCT00212056
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02033434
Drug: Intranasal Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomized Intranasal Ketamine, 50mg
Trial: NCT00149890
Drug: Cyclosporine/cyclosporine microemulsion
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
Trial: NCT00938197
Drug: Fimasartan
RxNorm normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan (1d\~7d) Amlodipine (12d\~14d) Fimasartan + Amlodipine(15d\~21d)
Trial: NCT00938197
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine (1d\~10d) Amlodipine (25d\~27d) Fimasartan + Amlodipine(28d\~34d)
Trial: NCT04341311
Drug: Marizomib
RxNorm normalized name: Marizomib
DrugBank: Marizomib (DB11762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Intravenously initially given every other week over a 28 day course but will go to weekly x 3 and weekly x 4 as the dose levels increase Up to 26 courses.
Trial: NCT04341311
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: - Panobinostat: Oral dosage is given 3 times weekly, every other week over a 28 day course
Trial: NCT00853866
Drug: reboxetine
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
Trial: NCT01748097
Drug: sodium bicarbonate 4.2%
RxNorm normalized name: Sodium Bicarbonate 4.2% Intravenous Solution
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04652076
Drug: NP137
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant humanized IgG1 monoclonal antibody against Netrin 1. NP137 will be administred IV, Q3W until disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, pregnancy or SMPC guidance, whichever occurs first.
Trial: NCT04652076
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Humanised monoclonal anti-programmed cell death-1 (PD-1) antibody will be administred in IV Q3W. A maximum 35 cycles of treatments (approximately 2 years) with pembrolizumab can be administered to patients.
Trial: NCT04652076
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
Trial: NCT04652076
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
Trial: NCT00391755
Drug: ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. ramelteon 8mg po qhs with sleep and headache diary~2. placebo 1 po qhs with sleep and headache diary
Trial: NCT01152190
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily for 8 weeks
Trial: NCT00834834
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
Trial: NCT00687388
Drug: selective alpha 1-blockers
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
Trial: NCT00191334
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
Trial: NCT00191334
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
Trial: NCT02173106
Drug: steroid & Cyclosporin
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
Trial: NCT03140657
Drug: Nanocurcumin
DrugBank: Cumin (DB10864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months
Trial: NCT00132119
Drug: nalmefene HCl
RxNorm normalized name: nalmefene HCl
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
Trial: NCT00995150
Drug: LNG20
RxNorm normalized name: Levonorgestrel 20 mcg
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: levonorgestrel-releasing intrauterine system for contraception
Trial: NCT00995150
Drug: Mirena
RxNorm normalized name: Mirena
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mirena intrauterine system
Trial: NCT01463046
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8~Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5~Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8
Trial: NCT01463046
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.~Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.~Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.
Trial: NCT01463046
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.~Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.~Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.
Trial: NCT01649180
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
Trial: NCT01291563
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule of moxifloxacin (400 mg/capsule) on Day 2
Trial: NCT01291563
Drug: Moxifloxacin placebo
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule of moxifloxacin placebo on Day 2
Trial: NCT02545972
Drug: tacrolimus extended release
RxNorm normalized name: Tacrolimus Extended Release Capsules
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily dosing of tacrolimus
Trial: NCT03860844
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous
Trial: NCT03860844
Drug: Dexamethasone or equivalent
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
Trial: NCT03860844
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT03860844
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT03860844
Drug: Liposomal daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT03512756
Drug: SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)
RxNorm normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily oral therapy for cancer
Trial: NCT01348880
Drug: Vardenafil ODT, (Staxyn, BAY38-9456)
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 10 mg of vardenafil ODT, taken without water
Trial: NCT03860844
Drug: Daunorubicin (nonliposomal)
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Trial: NCT03860844
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT03860844
Drug: Filgrastim or equivalent
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT03860844
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT03860844
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Trial: NCT03860844
Drug: Pegaspargase (PEG) Asparaginase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Trial: NCT03860844
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Trial: NCT03860844
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: PO
Trial: NCT03860844
Drug: L - Asparaginase (Erwinase)
RxNorm normalized name: asparaginase Injection [Erwinaze]
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular
Trial: NCT00411099
Drug: agomelatine
RxNorm normalized name: agomelatine
DrugBank: Agomelatine (DB06594)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01948804
Drug: GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01948804
Drug: GnRH antagonist protocol (Cetrotide, Serono)
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01979354
Drug: Spinal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.15 mg spinal morphine
Trial: NCT03463135
Drug: Glucopyranosyl Lipid A (GLA)
RxNorm normalized name: Glucopyranosyl Lipid A Stable Emulsion
DrugBank: G100 (DB17244)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
Trial: NCT03463135
Drug: Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution Route of administration: Sublingual
Trial: NCT03319706
Drug: Torrent's Olmesartan Medoxomil Tablets 40 mg
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02845999
Drug: fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: day -6 to day -2 : fludarabine 25 mg/m2
Trial: NCT02517697
Drug: 14 Nitrogen (N) Sodium Nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrogen (DB09152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral formulation of sodium nitrite 40 mg three times daily for 12 weeks
Trial: NCT02845999
Drug: interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
Trial: NCT02135510
Drug: metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02135510
Drug: dexamethason
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02135510
Drug: palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04487236
Drug: ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
Trial: NCT04487236
Drug: ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
Trial: NCT04487236
Drug: ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle
Trial: NCT04487236
Drug: ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose
Trial: NCT01441934
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment
Trial: NCT01441934
Drug: Sugar pills
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo t.i.d.
Trial: NCT03799536
Drug: Sotalol
RxNorm normalized name: Sotalol
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sotalol, Tablets,160 mg, manufactured by Pharmtechnology LLC, Belarus
Trial: NCT03799536
Drug: Sotalex
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sotalex, Tablets,160 mg, manufactured by Bristol-Myers Squibb GmbH \& Co. KGaA, Germany
Trial: NCT01257074
Drug: Acyclovir 50mg/g
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream, dose 5 times daily during 5 days
Trial: NCT01257074
Drug: Penciclovir 10mg/g
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream, dose 5 times daily during 5 days
Trial: NCT00451256
Drug: AVI-5126
RxNorm normalized name: AVI-5126
DrugBank: AVI-5126 (DB05726)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00396851
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01886352
Drug: Standard Injection of Levobupivacaine in portal sites.
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
Trial: NCT01886352
Drug: Additional injection of 0,5% levobupivacaine.
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
Trial: NCT01886352
Drug: Intraperitoneal atomization of levobupivacaine.
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~1. Each subdiaphragmatic area 0.05 ml/kg~2. Dome of abdomen then settling onto bowel 0.05 ml/kg~3. Surgical dissection site 0.05 ml/kg~4. At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg.
Trial: NCT00952952
Drug: Mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00414999
Drug: TG100801
DrugBank: G100 (DB17244)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04926571
Drug: Dexamethasone Oral
RxNorm normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: New users of Dexamethasone